

Hikma Pharmaceuticals PLC

Voting Results of 2021 Annual General Meeting

LONDON, 23 April 2021 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting (“AGM”), held at 1 New Burlington Place, W1S 2HR, London on 23 April 2021 commenced at 1:00 pm. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 15 and 17 were passed as ordinary resolutions and Resolutions 16 and 18 to 22 were passed as special resolutions.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the to the FCA’s Electronic Submission System and will be available from the National Storage Mechanism.

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 24 February 2021) is set out below. The number of Ordinary Shares in issue on 23 April 2021 was 243,604,637. There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 230,771,404.

Resolution	Votes For	%	Votes Against	%	Total Cast	Withheld
1. To receive the 2020 report and accounts	176,723,133	100.0	16,692	0	176,739,825	1,537,096
2. To approve a final dividend of 34 cents per share	178,275,824	100.0	152	0	178,275,976	945
3. To re-appoint PricewaterhouseCoopers LLP as auditors	177,053,202	99.3	1,222,474	0.7	178,275,676	1,245
4. To authorise the Audit Committee to determine the auditors’ remuneration	178,174,755	99.9	100,365	0.1	178,275,120	1,801
5. To elect Douglas Hurt as a director	174,859,594	98.1	3,414,131	1.9	178,273,725	3,196
6. To re-elect Said Darwazah as a director	171,553,543	97.2	4,923,908	2.8	176,477,451	1,799,470
7. To re-elect Siggí Olafsson as a director	176,112,071	98.8	2,163,336	1.2	178,275,407	1,514
8. To re-elect Mazen Darwazah as a director	171,246,066	96.1	6,949,669	3.9	178,195,735	81,186
9. To re-elect Patrick Butler as a director	172,831,258	97.0	5,434,621	3.1	178,265,879	11,041
10. To re-elect Ali Al-Husry as a director	175,142,703	98.3	3,053,032	1.7	178,195,735	81,186
11. To re-elect Dr. Pamela Kirby as a director	167,790,753	95.1	8,655,778	4.9	176,446,531	1,830,390
12. To re-elect John Castellani as a director	175,101,327	98.9	1,975,760	1.1	177,077,087	1,199,834
13. To re-elect Nina Henderson as a director	175,403,863	98.4	2,871,070	1.6	178,274,933	1,988

Resolution	Votes For	%	Votes Against	%	Total Cast	Withheld
14. To re-elect Cynthia Schwalm as a director	154,099,252	86.5	24,120,681	13.5	178,219,933	56,988
15. To approve the remuneration report for the year ended 31 December 2020	160,014,990	90.4	17,063,364	9.6	177,078,354	1,198,566
16. To approve the adoption of the new articles of association for the Company	177,680,870	99.7	593,294	0.3	178,274,164	2,757
17. Authority to allot shares	154,848,864	86.9	23,426,822	13.1	178,275,686	1,235
18. To dis-apply pre-emption rights for general purposes	177,563,944	99.6	711,824	0.4	178,275,768	1,153
19. To dis-apply pre-emption rights for an acquisition or other capital investment	174,606,709	97.9	3,668,585	2.1	178,275,294	1,627
20. To authorise the Company to purchase its own shares	176,712,127	99.2	1,480,842	0.8	178,192,969	83,952
21. To authorise the Company to hold general meetings on no less than 14 clear days' notice	169,544,820	95.1	8,731,027	4.9	178,275,847	1,074

Declaration of final dividend

The dividend of 34 cents per share will be paid on 26 April 2021 to shareholders on the register on 19 March 2021. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be \$1.3762998 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa \$1 to 0.709JD.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Peter Speirs
Company Secretary

+44 20 7399 2670

Susan Ringdal
EVP, Strategic Planning and Global Affairs

+44 20 7399 2670

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.